A study of extracorporeal photopheresis (ECP) in 71 patients has shown that the procedure is effective in treating steroid-refractory or -dependent acute GVHD (aGVHD) or chronic GVHD (cGVHD) with lower severity in the early stages. The aGVHD overall response rate (ORR) and complete aGVHD-free survival for ECP was 65% and 50% respectively. Grade II and III aGVHD ORR response rate was 81% and 67% respectively, with no response seen in patients with grade IV aGVHD. The ORR for ECP in cGVHD was 81% while the complete cGVHD-free survival was 50%. The study also showed that the total nucleated cells and lymphocytes collected during the first eight ECP procedures had no effect on treatment response rates for aGVHD and cGVHD.
Choose a Topic
- All Topics
- Unrelated Donor HCT
- AML
- Patient Eligibility
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Outcomes of Extracorporeal Photopheresis Better in Early Stage GVHD
Apr 2015